secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2026-09-15T12:30:50+00:00
Accession:  0001104659-26-107721
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Scholar Rock's ISEMBYLD for SMA; company clarifies post-marketing safety commitments
--------------------------------------------------------------------------------

- FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults/children 2+ on SMN2-targeted treatment.
- Corrects prior statement: FDA requires a pregnancy safety study and 15-day fracture alert reports as post-marketing commitments.
- Scholar Rock will conduct the study and submit fracture reports in compliance with FDA's request.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926107721/0001104659-26-107721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926107721/tm2625438d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-107721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer